Abstracts tagged "systemic sclerosis and tocilizumab"

Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki¹, Satoshi Ebata¹, Kouki Nakamura¹, Yoshihide Asano¹, Yutaka Kazoe², Kazuma Mawatari², Takehiko Kitamori² and Shinichi Sato¹, ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Judit Lluch¹, Ivan Castellvi², J Alegre³, Pablo Juárez¹, Joan Miquel Nolla¹ and Francisco Javier Narváez⁴, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
Abstract Number: 969 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
Dinesh Khanna¹, Christopher Denton², Helen Spotswood³, Angelika Jahreis⁴, Jacob M. van Laar⁵, Laura Burke⁶, Celia J. F. Lin⁴, Janet E. Pope⁷, Yannick Allanore⁸, Ulf Müller-Ladner⁹, Jeffrey Siegel⁶, Daniel E. Furst¹⁰ and faSScinate Clinical Trial Investigators, ¹University of Michigan, Ann Arbor, MI, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, ⁴Genentech, South San Francisco, CA, ⁵University Medical Center Utrecht, Utrecht, Netherlands, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology, Paris Descartes University, Paris, France, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a debilitating disease with few treatment options. Interleukin-6 (IL-6) appears to play a role in SSc pathogenesis (J Rheumatol 1998;25:308;…
Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting
Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Thierry Sornasse¹, Haiyin Chen¹, Lisa Rice², Giuseppina Stifano², Angelika Jahreis¹, Jeffrey Siegel¹ and Robert Lafyatis², ¹Genentech, South San Francisco, CA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna¹, Christopher P. Denton², Jacob M. van Laar³, Angelika Jahreis⁴, Sabrina Cheng⁴, Helen Spotswood⁵, Jeffrey Siegel⁴ and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS⁶, ¹University of Michigan Health System, Ann Arbor, MI, ²University College London Medical School, London, United Kingdom, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶University of California, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…